Global Asthma and COPD Drugs Market is expected to reach USD 62.32 billion by 2028

The Global Asthma and COPD Drugs Market is expected to reach USD 62.32 billion by 2028 from USD 43.19 billion in 2019, growing at a CAGR of 4.2% during the forecast period. Increasing asthma and COPD incidence and prevalence, advances in technology, and the rising senescent population is expected to propel the asthma and COPD drugs market during the forecast period.

Key Developments in the Asthma and COPD Drugs Market:
• In 2016, GlaxoSmithKline bought global rights to an experimental drug from Johnson and Johnson, raising its bet on a new generation of biotech medicines for severe asthma. The British drugmaker launched Nucala, its first injectable biological asthma drug, and is looking for additional treatments to help more patients who are still struggling with breathing problems.
• In 2018, AstraZeneca unloaded rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the US royalties for the drugs. Covis already commercializes the three drugs in the US, but upon closing, it will own them.
• In 2015, AstraZeneca announced that it has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited (“Takeda”). The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Texas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).

Companies Covered: Major Companies profiled in the report which are key players in the global asthma and COPD drugs market are Abbott Laboratories, Astrazeneca, Boehringer Ingelheim, Glaxosmithkline, Merck and Co., Grifols, Novartis AG, Pfizer, Roche Holding AG, and Teva Pharmaceutical.

Leave a Reply

Your email address will not be published. Required fields are marked *